The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Self-citationFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Self-citationNilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Saglio, G., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912614 · Cited by 1,678
Self-citationDasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589
Self-citationMahon, F.-X., Réa, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Legros, L., Charbonnier, A., Guerci, A., Varet, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70233-3 · Cited by 1,550
Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,291
Self-citationBaccarani, M. (2006) · Blood · doi:10.1182/blood-2006-02-005686 · Cited by 1,277
Hughes, T. (2006) · Blood · doi:10.1182/blood-2006-01-0092 · Cited by 1,199
Hochhaus, A., O'Brien, S. G., Guilhot, F., Druker, B. J., Branford, S., Foroni, L., Goldman, J. M., Müller, M. C., Radich, J. P., Rudoltz, M., et al. (2009) · Leukemia · doi:10.1038/leu.2009.38 · Cited by 856
Self-citationRoss, D. M., Branford, S., Seymour, J. F., Schwarer, A. P., Arthur, C., Yeung, D. T., Dang, P., Goyne, J. M., Slader, C., Filshie, R. J., et al. (2013) · Blood · doi:10.1182/blood-2013-02-483750 · Cited by 710
Cited by
Khoury, J. D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J. F., Bejar, R., Berti, E., Busque, L., Chan, J. K. C., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01613-1 · Cited by 4,274
Self-citationEuropean LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0776-2 · Cited by 1,547
Self-citationLong-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Hochhaus, A., Larson, R. A., Guilhot, F., Radich, J. P., Branford, S., Hughes, T. P., Baccarani, M., Deininger, M. W., Cervantes, F., Fujihara, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609324 · Cited by 1,285
Self-citationNetwork-based prediction of drug combinations
Cheng, F., Kovács, I. A., & Barabási, A.-L. (2019) · Nature Communications · doi:10.1038/s41467-019-09186-x · Cited by 800
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
Wylie, A. A., Schoepfer, J., Jahnke, W., Cowan-Jacob, S. W., Loo, A., Furet, P., Marzinzik, A. L., Pelle, X., Donovan, J., Zhu, W., et al. (2017) · Nature · doi:10.1038/nature21702 · Cited by 614
Metadata
- Authors
- Kalmanti, L., Saussele, S., Lauseker, M., Müller, M. C., Dietz, C. T., Heinrich, L., Hanfstein, B., Proetel, U., Fabarius, A., Krause, S. W., Rinaldetti, S., Dengler, J., Falge, C., Oppliger-Leibundgut, E., Burchert, A., Neubauer, A., Kanz, L., Stegelmann, F., Pfreundschuh, M., Spiekermann, K., Scheid, C., Pfirrmann, M., Hochhaus, A., Hasford, J., Hehlmann, R., & for the SAKK and the German CML Study-Group
- Venue
- Leukemia
- Published
- 2015-02-13
- Volume
- 29
- Issue
- 5
- Pages
- 1123-1132
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W1998406030
- Cited by
- 277
- References
- 44
- FWCI
- 24.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. https://app.cochat.ai/papers/10.1038/leu.2015.36
- The paper
- Kalmanti, L., Saussele, S., Lauseker, M., Müller, M. C., Dietz, C. T., Heinrich, L., Hanfstein, B., Proetel, U., Fabarius, A., Krause, S. W., Rinaldetti, S., Dengler, J., Falge, C., Oppliger-Leibundgut, E., Burchert, A., Neubauer, A., Kanz, L., Stegelmann, F., Pfreundschuh, M., . . . for the SAKK and the German CML Study-Group. (2015). Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. https://doi.org/10.1038/leu.2015.36
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.